Search

LEIDEN, Pays-Bas et CAMBRIDGE, Massachusetts, 18 déc. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.

LEIDEN, the Netherlands, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5Rx, jetzt QR-1123, für autosomal-dominante Retinitis pigmentosa (adRP), eine seltene vererbte Form der Blindheit ohne zugelassene Therapie

ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy